|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/22 | |
| A61K 45/06 |
| (11) | Patento numeris | 1962903 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 06820476.7 |
| Europos patento paraiškos padavimo data | 2006-12-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2008-09-03 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2013-03-13 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2006/004611 |
| Data | 2006-12-12 |
| (87) | Numeris | WO 2007/068895 |
| Data | 2007-06-21 |
| (30) | Numeris | Data | Šalis |
| 750551 P | 2005-12-15 | US |
| (72) |
BROWN, Jeffrey, Lester, US
EMERY, Stephen, Charles, GB
BLAKEY, David, Charles, GB
|
| (73) |
MedImmune Limited,
Milstein Building Granta Park, Cambridge CB21 6GH,
GB
|
| (54) | COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER |
| COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER |